Aurobindo Pharma’s drug for HIV infection gets USFDA nod
DSIJ Intelligence / 21 Aug 2017
A drug produced by Aurobindo Pharma for the treatment of HIV-1 infection has received tentative approval from the US Food & Drug Administration (USFDA) under the US President’s Emergency Plan for AIDS Relief (PEPFAR).
A drug produced by Aurobindo Pharma for the treatment of HIV-1 infection has received tentative approval from the US Food & Drug Administration (USFDA) under the US President’s Emergency Plan for AIDS Relief (PEPFAR). This new drug application is for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) tablets of 50 mg, 300 mg, and 300 mg, respectively.
The product is used as a complete regimen in adults and pediatric patients weighing 40 kg and more. The triple combination product is expected to be launched in sub-Saharan Africa in Q3FY18. ViiV Healthcare and Aurobindo Pharma signed a licensing agreement in 2014 that allows Aurobindo Pharma to supply Dolutegravir 50 mg in 92 licensed countries following completion of required local regulatory approval processes.
Meanwhile, Aurobindo Pharma is trading at Rs 704.50, up by 0.14% in the pre-market session of Monday.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.